Skip to main content
Beat Cancer EU Website Logo
Standardizing Use of MAP Kinase Inhibitors in Pediatric Cancer Treatment Outlined in European Journal of Cancer.
ScienceAllPublication

Standardizing Use of MAP Kinase Inhibitors in Pediatric Cancer Treatment Outlined in European Journal of Cancer.

How to make latest cancer therapies also available for children with rare cancers

Year:2022

How adult drugs from the group of MAP kinase inhibitors can also be used in children with cancer in a standardized manner worldwide has now been outlined in a statement in the renowned European Journal of Cancer.

The authors of this review are stakeholders from all relevant fields. A major goal of the initiative is to test the most effective and tolerable MAP kinase inhibitor in clinical trials, thus enabling rapid market approval and availability for children.

Discussion & Questions

Note: Comments are for discussion and clarification only. For medical advice, please consult with a healthcare professional.

Leave a Comment

Minimum 10 characters, maximum 2000 characters

No comments yet

Be the first to share your thoughts!